The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism
Open accessAbstract
Cognitive deficits in schizophrenia remain an unmet clinical need. Improved understanding of the neuro- and psychopathology of these deficits depends on the availability of carefully validated animal models which will assist the development of novel therapies. There is much evidence that at least some of the pathology and symptomatology (particularly cognitive and negative symptoms) of schizophrenia results from a dysfunction of the glutamatergic system which may be modelled in animals through the use of NMDA receptor antagonists. The current review examines the validity of this model in rodents. We review the ability of acute and sub-chronic treatment with three non-competitive NMDA antagonists; phencyclidine (PCP), ketamine and MK801 (dizocilpine) to produce cognitive deficits of relevance to schizophrenia in rodents and their subsequent reversal by first- and second-generation antipsychotic drugs. Effects of NMDA receptor antagonists on the performance of rodents in behavioural tests assessing the various domains of cognition and negative symptoms are examined: novel object recognition for visual memory, reversal learning and attentional set shifting for problem solving and reasoning, 5-Choice Serial Reaction Time for attention and speed of processing; in addition to effects on social behaviour and neuropathology. The evidence strongly supports the use of NMDA receptor antagonists to model cognitive deficit and negative symptoms of schizophrenia as well as certain pathological disturbances seen in the illness. This will facilitate the evaluation of much-needed novel pharmacological agents for improved therapy of cognitive deficits and negative symptoms in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data
Ennaceur, A., & Delacour, J. (1988) · Behavioural Brain Research · doi:10.1016/0166-4328(88)90157-x · Cited by 3,223 · cited 1×
“Ennaceur and Delacour (1988) described the NOR test for rodents, which was based on the differential exploration of familiar and new objects.”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
A continuous performance test of brain damage
Rosvold, H. E., Mirsky, A. F., Sarason, I., Bransome, E. D., & Beck, L. H. (1956) · Journal of Consulting Psychology · doi:10.1037/h0043220 · Cited by 2,261
A simple objective technique for measuring flexibility in thinking
Berg, E. A. (1948) · The Journal of General Psychology · doi:10.1080/00221309.1948.9918159 · Cited by 2,255
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Meta-analysis of regional brain volumes in schizophrenia
Wright, I. C., Rabe-Hesketh, S., Woodruff, P. W. R., David, A. S., Murray, R. M., & Bullmore, E. T. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.16 · Cited by 1,662
Why sex matters for neuroscience
Cahill, L. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1909 · Cited by 1,540
Medial Frontal Cortex Mediates Perceptual Attentional Set Shifting in the Rat
Birrell, J. M., & Brown, V. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04320.2000 · Cited by 1,421 · cited 5×
“The perceptual attentional set-shifting task (Birrell and Brown, 2000) investigates the ability of a rat to learn a rule and form an attentional set within the same sorting category (intradimensional shift - IDS), as well as the ability to shift attentional set between different sorting categories…”
BackgroundMethodInfluentialChild developmental risk factors for adult schizophrenia in the British 1946 birth cohort
JONES, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90569-x · Cited by 1,353
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry
Robbins, T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1154-7 · Cited by 1,282
Guidotti, A., Auta, J., Davis, J. M., Gerevini, V. D., Dwivedi, Y., Grayson, D. R., Impagnatiello, F., Pandey, G., Pesold, C., Sharma, R., et al. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.11.1061 · Cited by 1,206
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Akbarian, S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160008002 · Cited by 1,002
Hashimoto, T., Volk, D. W., Eggan, S. M., Mirnics, K., Pierri, J. N., Sun, Z., Sampson, A. R., & Lewis, D. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06315.2003 · Cited by 938
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917 · cited 1×
“…exploration of the mechanisms by which NMDA receptor antagonism provides a relevant model of schizophrenia in animals (Jentsch and Roth, 1999; Coyle, 2006; Large, 2007-focusing on novel therapies; Morris et al. 2005; Mouri et al. 2007); the use of isolation rearing as a neurodevelopmental…”
BackgroundDopamine receptors and the dopamine hypothesis of schizophrenia
Seeman, P. (1987) · Synapse · doi:10.1002/syn.890010203 · Cited by 880
Fone, K. C. F., & Porkess, M. V. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.003 · Cited by 864
Lawrie, S. M., & Abukmeil, S. S. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.172.2.110 · Cited by 843
Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.237 · Cited by 697
Malhotra, M. D. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00036-5 · Cited by 680
The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents
Dere, E., Huston, J. P., & De Souza Silva, M. A. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.01.005 · Cited by 675
Impaired Attention, Genetics, and the Pathophysiology of Schizophrenia
Cornblatt, B. A., & Keilp, J. G. (1994) · Schizophrenia Bulletin · doi:10.1093/schbul/20.1.31 · Cited by 666
Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat
McAlonan, K., & Brown, V. J. (2003) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.09.019 · Cited by 618
Genes for schizophrenia? Recent findings and their pathophysiological implications
Harrison, P. J., & Owen, M. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12379-3 · Cited by 597
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585
Object recognition memory: Neurobiological mechanisms of encoding, consolidation and retrieval
Winters, B. D., Saksida, L. M., & Bussey, T. J. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.04.004 · Cited by 572
Downes, J. J., Roberts, A. C., Sahakian, B. J., Evenden, J. L., Morris, R. G., & Robbins, T. W. (1989) · Neuropsychologia · doi:10.1016/0028-3932(89)90128-0 · Cited by 527
Chudasama, Y., Passetti, F., Rhodes, S. E. V., Lopian, D., Desai, A., & Robbins, T. W. (2003) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.09.020 · Cited by 518 · cited 1×
“Other brain regions that have important significance in correct performance of the 5-CSR task include the anterior cingulate cortex, striatum and the thalamus (Muir et al., 1994; Muir et al., 1996; Rogers et al., 2001; Robbins, 2002; Chudasama et al., 2003)”
BackgroundMuir, J. L., Everitt, B. J., & Robbins, T. W. (1996) · Cerebral Cortex · doi:10.1093/cercor/6.3.470 · Cited by 502
A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives
Benes, F. M., Kwok, E. W., Vincent, S. L., & Todtenkopf, M. S. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00138-3 · Cited by 470
KOLB, B., & WHISHAW, I. Q. (1983) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198307000-00008 · Cited by 463
Zhang, Z. J., & Reynolds, G. P. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00188-8 · Cited by 460 · cited 1×
“Deficits in PV-immunoreactive cells have been reported in both the frontal cortex (Beasley and Reynolds, 1997; Beasley et al., 2002; Refs) and hippocampus (Zhang and Reynolds, 2002) in postmortem brain tissue from patients diagnosed with schizophrenia.”
BackgroundParvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
BEASLEY, C., & REYNOLDS, G. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00122-3 · Cited by 426
Muir, J., Everitt, B., & Robbins, T. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-04-02313.1994 · Cited by 421
The cerebral cortex of the rat
(1991) · Comparative Biochemistry and Physiology Part A: Physiology · doi:10.1016/0300-9629(91)90172-9 · Cited by 410
Positive and Negative Symptoms in Schizophrenia: A Critical Reappraisal
Andreasen, N. C. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810190015002 · Cited by 410
Braff, D. L. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340023003 · Cited by 399
Jentsch, J. D., Redmond, D. E., Elsworth, J. D., Taylor, J. R., Youngren, K. D., & Roth, R. H. (1997) · Science · doi:10.1126/science.277.5328.953 · Cited by 398
Beasley, C. L., Zhang, Z. J., Patten, I., & Reynolds, G. P. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01360-4 · Cited by 374
Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage
Pantelis, C., Barber, F. Z., Barnes, T. R. E., Nelson, H. E., Owen, A. M., & Robbins, T. W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00156-x · Cited by 346
Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia
Becker, A., Peters, B., Schroeder, H., Mann, T., Huether, G., & Grecksch, G. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00080-0 · Cited by 339
Hypofrontality in schizophrenia: a meta‐analysis of functional imaging studies
Hill, K., Mann, L., Laws, K. R., Stephenson, C. M. E., Nimmo‐Smith, I., & McKenna, P. J. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00376.x · Cited by 333
Jentsch, J. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00034-1 · Cited by 320
(2010) · The Tomb of Tut-Ankh-Amen · doi:10.1017/cbo9780511722349.008 · Cited by 313
PCP: from pharmacology to modelling schizophrenia
Morris, B. J., Cochran, S. M., & Pratt, J. A. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.008 · Cited by 308
Neural circuits subserving behavioral flexibility and their relevance to schizophrenia
Floresco, S. B., Zhang, Y., & Enomoto, T. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.001 · Cited by 298 · cited 6×
“, twice daily for 5 days followed by a 10 day washout period), did not impair setshifting ability in male Long–Evans rats in either a cross-maze-based task or in an operant procedure (Floresco et al., 2009).”
BackgroundMethodResultInfluentialYoung, J. W., Powell, S. B., Risbrough, V., Marston, H. M., & Geyer, M. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.004 · Cited by 298
Boulougouris, V., Dalley, J. W., & Robbins, T. W. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.02.005 · Cited by 297 · cited 1×
“These studies are also supported by recent data showing OFC lesions in male hooded-Lister rats produced a deficit in reversal learning ability (Boulougouris et al., 2007).”
ResultMouri, A., Noda, Y., Enomoto, T., & Nabeshima, T. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.019 · Cited by 266
NMDA receptors and schizophrenia
KRISTIANSEN, L., HUERTA, I., BENEYTO, M., & MEADORWOODRUFF, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.013 · Cited by 246
GRAYSON, B., IDRIS, N., & NEILL, J. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.06.012 · Cited by 243
Self-citationInterleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia
Behrens, M. M., Ali, S. S., & Dugan, L. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4457-08.2008 · Cited by 241
Grottick, A. J., & Higgins, G. A. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00305-3 · Cited by 240 · cited 2×
“The group suggested that the increase in the time taken to respond is due to PCP interfering with the animal’s ability to processes cognitive information, consistent with previous studies (Grottick & Higgins, 2000).”
ResultInfluence of gender on working and spatial memory in the novel object recognition task in the rat
Sutcliffe, J. S., Marshall, K. M., & Neill, J. C. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.10.029 · Cited by 240
Self-citationRujescu, D., Bender, A., Keck, M., Hartmann, A. M., Ohl, F., Raeder, H., Giegling, I., Genius, J., McCarley, R. W., Möller, H.-J., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.029 · Cited by 239
Cochran, S. M., Kennedy, M., McKerchar, C. E., Steward, L. J., Pratt, J. A., & Morris, B. J. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300031 · Cited by 236
de Lima, M. N. M., Laranja, D. C., Bromberg, E., Roesler, R., & Schröder, N. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.05.016 · Cited by 215
Abi-Dargham, A., van de Giessen, E., Slifstein, M., Kegeles, L. S., & Laruelle, M. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.007 · Cited by 213 · cited 1×
“…release more dopamine at the synapse on stimulation with amphetamine than normal control groups suggesting increased midbrain dopamine activity (Abi-Dargham et al. 2009), a revision of this theory became necessary when it was observed that the negative and cognitive symptoms of schizophrenia…”
BackgroundAbdul-Monim, Z., Neill, J. C., & Reynolds, G. P. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107067097 · Cited by 206
Self-citationThaker, G. K., & Carpenter, W. T. (2001) · Nature Medicine · doi:10.1038/89040 · Cited by 200
(+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia
Rung, J. P., Carlsson, A., Rydén Markinhuhta, K., & Carlsson, M. L. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.004 · Cited by 199
Keilhoff, G., Becker, A., Grecksch, G., Wolf, G., & Bernstein, H.-G. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.03.039 · Cited by 199
Social Interaction Deficits Caused by Chronic Phencyclidine Administration are Reversed by Oxytocin
Lee, P. R., Brady, D. L., Shapiro, R. A., Dorsa, D. M., & Koenig, J. I. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300722 · Cited by 199
Animal models for the negative symptoms of schizophrenia
Ellenbroek, B. A., & Cools, A. R. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00006 · Cited by 199
Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia
Reynolds, G. P., Czudek, C., & Andrews, H. B. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90039-5 · Cited by 199
PDE10A inhibition reverses subchronic PCP‐induced deficits in attentional set‐shifting in rats
Rodefer, J. S., Murphy, E. R., & Baxter, M. G. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03937.x · Cited by 199
King, M. V., Sleight, A. J., Woolley, M. L., Topham, I. A., Marsden, C. A., & Fone, K. C. F. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.03.012 · Cited by 197
The epidemiology of onset and course of schizophrenia
an der Heiden, W., & H�fner, H. (2000) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060070004 · Cited by 190
Karasawa, J.-I., Hashimoto, K., & Chaki, S. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.07.033 · Cited by 173
Jones, G. H., Marsden, C. A., & Robbins, T. W. (1991) · Behavioural Brain Research · doi:10.1016/s0166-4328(05)80050-6 · Cited by 172
Steinpreis, R. E. (1996) · Behavioural Brain Research · doi:10.1016/0166-4328(95)00162-x · Cited by 171
Weisbrod, M., Kiefer, M., Marzinzik, F., & Spitzer, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00218-8 · Cited by 171
The GABAergic system in schizophrenia
Blum, B. P., & Mann, J. J. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002894 · Cited by 169
Egerton, A., Reid, L., McKerchar, C. E., MORRIS, B. J., & Pratt, J. A. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2109-y · Cited by 166
Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats
Sams‐Dodd, F. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199501000-00009 · Cited by 164
Behrens, M. M., & Sejnowski, T. J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.002 · Cited by 162
Wang, C. Z., Yang, S. F., Xia, Y., & Johnson, K. M. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301647 · Cited by 161 · cited 2×
“This treatment regime does not affect the CR subset (Wang et al., 2008).”
BackgroundHashimoto, K., Fujita, Y., Shimizu, E., & Iyo, M. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.07.002 · Cited by 159
Benes, F. M., Khan, Y., Vincent, S. L., & Wickramasinghe, R. (1996) · Synapse · doi:10.1002/(sici)1098-2396(199604)22:4<338::aid-syn5>3.0.co;2-c · Cited by 159
Sams-Dodd, F. (1999) · Reviews in the Neurosciences · doi:10.1515/revneuro.1999.10.1.59 · Cited by 158
Abdul-Monim, Z., Reynolds, G. P., & Neill, J. C. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.01.019 · Cited by 157
Self-citationNagai, T., Murai, R., Matsui, K., Kamei, H., Noda, Y., Furukawa, H., & Nabeshima, T. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1240-6 · Cited by 151
Fletcher, P. J., Tenn, C. C., Rizos, Z., Lovic, V., & Kapur, S. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0157-6 · Cited by 150
Murphy, E. R., Dalley, J. W., & Robbins, T. W. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2068-3 · Cited by 145
Executive function in schizophrenia.
Velligan, D. I., & Bow-Thomas, C. C. (1999) · PubMed · doi:10.1053/scnp00400024 · Cited by 143
Becker, A., & Grecksch, G. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.06.019 · Cited by 143
Neurocognitive Deficits in Schizophrenia
Goldberg, T. E., David, A. S., & Gold, J. M. (2003) · Wiley eBooks · doi:10.1002/9780470987353.ch10 · Cited by 142
Management of the Negative Symptoms of Schizophrenia: New Treatment Options
M??ller, H.-J. (2003) · CNS Drugs · doi:10.2165/00023210-200317110-00003 · Cited by 141
Rogers, R. D., Baunez, C., Everitt, B. J., & Robbins, T. W. (2001) · Behavioral Neuroscience · doi:10.1037/0735-7044.115.4.799 · Cited by 140 · cited 1×
“Other brain regions that have important significance in correct performance of the 5-CSR task include the anterior cingulate cortex, striatum and the thalamus (Muir et al., 1994; Muir et al., 1996; Rogers et al., 2001; Robbins, 2002; Chudasama et al., 2003)”
BackgroundChudasama, Y., & Robbins, T. W. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1805-y · Cited by 137
Braun, I., Genius, J., Grunze, H., Bender, A., Möller, H., & Rujescu, D. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.05.005 · Cited by 136
Amitai, N., Semenova, S., & Markou, A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0808-x · Cited by 132
Idris, N. F., Repeto, P., Neill, J. C., & Large, C. H. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2058-5 · Cited by 131
Self-citationQiao, H., Noda, Y., Kamei, H., Nagai, T., Furukawa, H., Miura, H., Kayukawa, Y., Ohta, T., & Nabeshima, T. (2001) · Neuroreport · doi:10.1097/00001756-200101220-00010 · Cited by 129
Stefani, M. R., & Moghaddam, B. (2005) · Behavioral Neuroscience · doi:10.1037/0735-7044.119.2.420 · Cited by 127
Rodefer, J. S., Nguyen, T. N., Karlsson, J.-J., & Arnt, J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301654 · Cited by 126
Slot, L. A. B., Kleven, M. S., & Newman‐Tancredi, A. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.05.013 · Cited by 123
Abekawa, T., Ito, K., Nakagawa, S., & Koyama, T. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0729-8 · Cited by 118
Silvestre, J. S., Nadal, R. A., S, M. A. P., & Ferr�, N. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)5:1<29::aid-da5>3.0.co;2-0 · Cited by 116
Egerton, A., Reid, L., McGregor, S., Cochran, S. M., MORRIS, B. J., & Pratt, J. A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1071-5 · Cited by 115
Goetghebeur, P., & Dias, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1132-9 · Cited by 113
Higgins, G. A., Ballard, T. M., Huwyler, J., Kemp, J. A., & Gill, R. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(02)00402-1 · Cited by 113
Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia
Hagan, J. J., & Jones, D. N. C. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi058 · Cited by 111
Paine, T. A., Tomasiewicz, H. C., Zhang, K., & Carlezon, W. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.017 · Cited by 109
Harich, S., Groß, G., & Bespalov, A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0742-y · Cited by 108
Abdul-Monim, Z., Reynolds, G. P., & Neill, J. C. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103017001700 · Cited by 108
Self-citationArnt, J., Bang‐Andersen, B., Grayson, B., Bymaster, F. P., Cohen, M. P., DeLapp, N. W., Giethlen, B., Kreilgaard, M., McKinzie, D. L., Neill, J. C., et al. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000659 · Cited by 108
Self-citationSams‐Dodd, F. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00161-9 · Cited by 102
Fujita, Y., Ishima, T., Kunitachi, S., Hagiwara, H., Zhang, L., Iyo, M., & Hashimoto, K. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.031 · Cited by 100
Large, C. H. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077712 · Cited by 98
Floresco, S., Geyer, M. A., Gold, L. H., & Grace, A. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi041 · Cited by 98
Roberts, E. (1972) · PubMed · Cited by 97
McLean, S. L., Beck, J. P., Woolley, M. L., & Neill, J. C. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.12.029 · Cited by 95
Self-citationBrigman, J. L., Ihne, J., Saksida, L. M., Bussey, T. J., & Holmes, A. (2009) · Frontiers in Behavioral Neuroscience · doi:10.3389/neuro.08.002.2009 · Cited by 91
Snigdha, S., & Neill, J. C. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.03.018 · Cited by 90
Self-citationEffects of sub-anesthetic doses of ketamine on rats' spatial and non-spatial recognition memory
Pitsikas, N., Boultadakis, A., & Sakellaridis, N. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.04.001 · Cited by 89
Greco, B., Invernizzi, R. W., & Carli, M. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2127-9 · Cited by 86
Orbital prefrontal cortex and guidance of instrumental behaviour in rats under reversal conditions
Bohn, I., Giertler, C., & Hauber, W. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(03)00008-1 · Cited by 83
McLean, S. L., Idris, N. F., Woolley, M. L., & Neill, J. C. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.009 · Cited by 79
Self-citationStability of set-shifting and planning abilities in patients with schizophrenia
Tyson, P. J., Laws, K. R., Roberts, K., & Mortimer, A. M. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.09.007 · Cited by 78
Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice
Chan, M., Chiu, P., Sou, J.-H., & Chen, H. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1103-1 · Cited by 77
TAIT, D. S., & BROWN, V. J. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1401.010 · Cited by 75
Idris, N., Neill, J., Grayson, B., Bang-Andersen, B., Witten, L. M., Brennum, L. T., & Arnt, J. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1702-5 · Cited by 74 · cited 10×
“We have also demonstrated efficacy of sertindole (Idris et al., 2010), and several novel agents including the 5-HT6 receptor antagonist, Lu AE58054 (Arnt et al. 2010); ampakines, CX546 and CX516 (Daamgard et al. 2010) and the full agonist at α7 nicotinic receptors, PNU282987 (McLean et al. 2010a).”
BackgroundResultInfluentialSelf-citationRole of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat
McLean, S. L., Woolley, M. L., Thomas, D. W., & Neill, J. C. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1618-0 · Cited by 74
Self-citationSnigdha, S., & Neill, J. C. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.10.012 · Cited by 74
Self-citationThe dopamine D3/D2 receptor agonist 7-OH-DPAT induces cognitive impairment in the marmoset
Smith, A. G., Neill, J. C., & Costall, B. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00230-5 · Cited by 71
Self-citationOn the nature of Wisconsin Card Sorting Test performance in schizophrenia
Haut, M. W., Cahill, J., Cutlip, W. D., Stevenson, J. M., Makela, E. H., & Bloomfield, S. M. (1996) · Psychiatry Research · doi:10.1016/0165-1781(96)02940-x · Cited by 71
Broberg, B. V., Dias, R., Glenthoj, B. Y., & Olsen, C. K. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.020 · Cited by 70
McKibben, C. E., Jenkins, T. A., Adams, H. N., Harte, M., & Reynolds, G. P. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.11.018 · Cited by 68
Self-citationThe NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats
van der Meulen, J. A. J., Bilbija, L., Joosten, R. N. J. M. A., de Bruin, J. P. C., & Feenstra, M. G. P. (2003) · Neuroreport · doi:10.1097/00001756-200312020-00018 · Cited by 65
Hagiwara, H., Fujita, Y., Ishima, T., Kunitachi, S., Shirayama, Y., Iyo, M., & Hashimoto, K. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.11.005 · Cited by 64
McLean, S. L., Grayson, B., Idris, N. F., Lesage, A. S., Pemberton, D. J., Mackie, C. E., & Neill, J. C. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.003 · Cited by 63
Self-citationBroberg, B. V., Glenthoj, B. Y., Dias, R., Larsen, D. B., & Olsen, C. K. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1540-5 · Cited by 59
Jenkins, T. A., Harte, M., McKibben, C. E., Elliott, J. J., & Reynolds, G. P. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.07.020 · Cited by 57
Self-citationExecutive function in schizophrenia: what impact do antipsychotics have?
O’Gráda, C., & Dinan, T. G. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.861 · Cited by 56
Boulay, D., Depoortère, R., Louis, C., Perrault, G., Griebel, G., & Soubrié, P. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.02.008 · Cited by 56
Depoortère, R., Auclair, A. L., Bardin, L., Slot, L. A. B., Kleven, M. S., Colpaert, F. C., Vacher, B., & Newman‐Tancredi, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707160 · Cited by 55
Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats
Paine, T. A., & Carlezon, W. A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.01.004 · Cited by 55
Damgaard, T., Larsen, D. B., Hansen, S. L., Grayson, B., Neill, J. C., & Plath, N. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.09.048 · Cited by 48
Self-citationBaviera, M., Invernizzi, R. W., & Carli, M. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0959-9 · Cited by 46
McLean, S. L., Neill, J. C., Idris, N. F., Marston, H. M., Wong, E. H. F., & Shahid, M. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.043 · Cited by 45
Self-citationAmitai, N., & Markou, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.08.025 · Cited by 43
Matsuoka, T., Sumiyoshi, T., Tanaka, K., Tsunoda, M., Uehara, T., Itoh, H., & Kurachi, M. (2005) · Brain Research · doi:10.1016/j.brainres.2005.06.035 · Cited by 40
NMDA receptor antagonism impairs reversal learning in developing rats.
Chadman, K. K., Watson, D. J., & Stanton, M. E. (2006) · Behavioral Neuroscience · doi:10.1037/0735-7044.120.5.1071 · Cited by 40
Laurent, V., & Podhorná, J. (2004) · Behavioural Pharmacology · doi:10.1097/00008877-200403000-00006 · Cited by 38
Katayama, T., Jodo, E., Suzuki, Y., Hoshino, K.-Y., Takeuchi, S., & Kayama, Y. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.01.002 · Cited by 36
Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia
Harvey, P. D., & McClure, M. M. (2006) · Drugs · doi:10.2165/00003495-200666110-00004 · Cited by 36
Dopamine antagonist effects on behavior maintained by cocaine and alfentanil in rhesus monkeys
Winger, G. D. (1994) · Behavioural Pharmacology · doi:10.1097/00008877-199404000-00005 · Cited by 28
Effect of MK‐801 on gene expressions in the amygdala of rats
Matsuoka, T., Tsunoda, M., Sumiyoshi, T., Takasaki, I., Tabuchi, Y., Seo, T., Tanaka, K., Uehara, T., Itoh, H., Suzuki, M., et al. (2007) · Synapse · doi:10.1002/syn.20455 · Cited by 27
Neurocognitive and social functioning in schizophrenia and other diagnoses
Addington, J., Addington, D. E., & Gasbarre, L. M. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00103-1 · Cited by 25
Functional Brain Imaging in Schizophrenia
Meyer‐Lindenberg, A., & Bullmore, E. T. (2010) · Wiley eBooks · doi:10.1002/9781444327298.ch17 · Cited by 23
Sutcliffe, J., Rhaman, F., Marshall, K. M., & Neill, J. C. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107083839 · Cited by 23
Self-citationWhite, I. M., Minamoto, T., Odell, J. R., Mayhorn, J., & White, W. O. (2009) · Brain Research · doi:10.1016/j.brainres.2009.02.024 · Cited by 22
Impaired social motivation and increased aggression in rats subchronically exposed to phencyclidine
Audet, M., Goulet, S., & Doré, F. Y. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.11.002 · Cited by 22
Distinct Contributions of Glutamate Receptor Subtypes to Cognitive Set‐Shifting Abilities in the Rat
Stefani, M. R., & Moghaddam, B. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.064 · Cited by 20
Rule shift under long-term PCP challenge in rats
Deschênes, A., Goulet, S., & Doré, F. Y. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.08.013 · Cited by 20
Idris, N. F. (2009) · Frontiers in Behavioral Neuroscience · doi:10.3389/neuro.08.008.2009 · Cited by 17
Self-citationStrategies for pharmacotherapy of schizophrenia
Arnt, J., Bang‐Andersen, B., Dias, R. D. S., & Bøgesø, K. P. (2008) · Drugs of the Future · doi:10.1358/dof.2008.033.09.1236966 · Cited by 17
Neurocognitive Deficits in Schizophrenia
Yager, J. (1996) · Journal watch · doi:10.1056/jp199606010000010 · Cited by 17
Cited by
Animal models of schizophrenia
Jones, C., Watson, D., & Fone, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01386.x · Cited by 771
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Update on Typical and Atypical Antipsychotic Drugs
Meltzer, H. Y. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050911-161504 · Cited by 433
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond
Krystal, J. H., Sanacora, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.026 · Cited by 406
Millan, M. J., Fone, K., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 347
Metadata
- Authors
- Neill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. K.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 128
- Issue
- 3
- Pages
- 419-432
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1986336245
- Cited by
- 530
- References
- 167
- FWCI
- 23.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.